Study S001782

Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02187250
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 45
Start: 2014-03
Primary completion: 2014-06
Lead sponsor: University Medical Centre Ljubljana
Conditions: PCOS; Obesity
Interventions: DRUG:metformin; DRUG:liraglutide; DRUG:roflumilast
Results posted: FALSE

Registered primary outcomes

The main outcome was change in body weight. [Patient's body weight was mesured at the base point and every four weeks during 12 weeks of clinical trial.]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023497	Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. Jensterle M, Journal of ovarian research	2015	Randomized trial	PMID 26032655 DOI	cites ClinicalTrials.gov:NCT02187250; registry reference DERIVED:26032655